First reported 18 hours ago -
Updated 17 hours ago -
CARLSBAD, Calif., Aug. 28, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) announced the initiation of a Phase 3 study evaluating ISIS-APOCIIIRx in patients with familial chylomicronemia syndrome (FCS). FCS is a rare orphan disease, characterized ...
[Published Nasdaq - 18 hours ago]